On June 16, 2025, Needham analyst Ami Fadia reiterated a "Hold" rating for Sage Therapeutics (SAGE, Financial). The rating remains unchanged from the previous assessment, marking a consistent outlook for the company's stock performance.
Notably, there was no adjustment to the price targets, both current and prior, for Sage Therapeutics (SAGE, Financial) in this latest update. The actions underscore the analyst's maintained position regarding the stock's potential in the market.
Investors in Sage Therapeutics (SAGE, Financial) might want to consider the reiterated rating as part of their broader analysis when evaluating the stock. The consistent "Hold" rating suggests a neutral stance, with no immediate recommendations for buying or selling the shares based on this particular analysis.
Wall Street Analysts Forecast
Based on the one-year price targets offered by 17 analysts, the average target price for Sage Therapeutics Inc (SAGE, Financial) is $8.05 with a high estimate of $12.00 and a low estimate of $5.00. The average target implies an upside of 20.13% from the current price of $6.70. More detailed estimate data can be found on the Sage Therapeutics Inc (SAGE) Forecast page.
Based on the consensus recommendation from 19 brokerage firms, Sage Therapeutics Inc's (SAGE, Financial) average brokerage recommendation is currently 2.9, indicating "Hold" status. The rating scale ranges from 1 to 5, where 1 signifies Strong Buy, and 5 denotes Sell.
Based on GuruFocus estimates, the estimated GF Value for Sage Therapeutics Inc (SAGE, Financial) in one year is $182.36, suggesting a upside of 2621.79% from the current price of $6.7. GF Value is GuruFocus' estimate of the fair value that the stock should be traded at. It is calculated based on the historical multiples the stock has traded at previously, as well as past business growth and the future estimates of the business' performance. More detailed data can be found on the Sage Therapeutics Inc (SAGE) Summary page.
